USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Race Oncology Ltd.

USPTO PatentsView assignee record - 6 granted patents across 2 technology areas, recorded in grant years 2018–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Race ranks #42,558 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 2 technology areas.

#42,558
of 49,997 US assignees by volume
6th percentile
by Innovation Score (19.1/100)
12.3
avg claims per patent
+0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R42558 · Foreign Corporation #42,558 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-LOW · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

  • GRANTS-MICRO 6 grants
  • LOWER-Q #42,558/49,997
  • PHOTO-FINISH Rad Technology…
  • CPC-NARROW A61P · 2 areas
  • INNOV-LOW 19.1/100
  • CLAIMS-RICH 12.3 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-FLAT +0% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Rad Technology Medical Systems LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Race’s 19.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Race

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Race's Innovation Score is 19.1/100 (6th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Race?

Each dot is one of Race’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Race’s own 12.3 claims/patent is at or below the 17.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Race vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 5.96.06.066.06.06.1 51015202530 Granted patents (volume) Avg claims / patent RTR Technologies, Inc. - 6, 22.33RTRRuntech Systems OY - 6, 16Runtech Systems OYRV Lizenz AG - 6, 17.17RV LizenzRVT Group Limited - 6, 9.5RVT GroupRad Technology Medical Systems LLC - 6, 25.67Rad Technology Me…RadiaDyne LLC - 6, 17.67RadiadyneRadiance Therapeutics, Inc. - 6, 7Radiance Therapeu…Radical Plastics, Inc. - 6, 17.67Radical PlasticsRace Oncology Ltd. - 6, 12.33Race Oncology
Race vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Race's grants concentrate

Race Oncology Ltd. is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (2 grants) versus a trough of 1 in 2019. By volume, Race sits between RTR Technologies, Inc. and Radical Plastics, Inc..

Who files at Race's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Race holds 6 patents at rank #42,617, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Race

By rank, the assignees closest to #42,617 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Race's primary technology class.

Race's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

19 6th percentile higher than 6% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 2018201920202021 2
USPTO utility patent grants by year · 2018–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table
Race Oncology Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2018 2 33.3%
2019 1 16.7%
2020 1 16.7%
2021 2 33.3%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Race Oncology Ltd.'s patent record in context - here's where to go next.

  • Race Oncology Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #42,558 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Race Oncology Ltd. against RTR Technologies, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 19.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.